Continue to meet or exceed healthcare partners’ expectations by providing on-time test results approximately 92 percent of the time.
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...